6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

diseases per page:

Showing 1 to 10 of 2,307 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05669170 (ClinicalTrials.gov)	January 2024	16/12/2022	Methylphenidate for Apathy in Veterans With Parkinson's Disease	Evaluating Safety and Potential Benefit of Methylphenidate as a Symptomatic Treatment for Apathy in ...	Parkinson Disease;Apathy	Behavioral: Psychosocial intervention;Drug: Methylphenidate	Ralph H. Johnson VA Medical Center	NULL	Not yet recruiting	40 Years	N/A	All	60	Phase 2	NULL
2	NCT05721911 (ClinicalTrials.gov)	June 2023	30/1/2023	Implementing a National Biobank of PD With WGS and Functional Assessment of Polygenic Inheritance by ...	Implementing a National Biobank of Genetic, Sporadic and Prodromic Parkinson's DiseaseWith Whole Gen ...	Parkinson Disease;REM Sleep Behavior Disorder	Genetic: whole genome sequencing	Neuromed IRCCS	NULL	Not yet recruiting	18 Years	N/A	All	230		Italy
3	NCT05709301 (ClinicalTrials.gov)	April 1, 2023	11/1/2023	Randomized Clinical Trial of Donepezil for the Treatment of Mild Cognitive Impairment in Parkinson's ...	Multicenter, Randomized, Double-blinded, Placebo-controlled Clinical Trial of Donepezil for the Trea ...	Parkinson Disease;Mild Cognitive Impairment	Drug: Donepezil Hydrochloride;Drug: Placebo	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	NULL	Not yet recruiting	50 Years	80 Years	All	120	Phase 2	NULL
4	NCT05634876 (ClinicalTrials.gov)	April 2023	23/11/2022	UB-312 in Patients With Synucleinopathies	A Phase 1b Clinical Trial of UB-312 in Patients With Synucleinopathies	Multiple System Atrophy;Parkinson Disease	Biological: UB-312 Injection;Biological: Placebo Injection	NYU Langone Health	NULL	Not yet recruiting	40 Years	75 Years	All	8	Phase 1/Phase 2	United States
5	NCT05636852 (ClinicalTrials.gov)	March 31, 2023	1/11/2022	Altropane Dose for Imaging Patients With Suspected Parkinson's Disease	An Open-label Multicenter Phase 2 Dose-evaluation Study of Altropane (123I) Injection for Striatal D ...	Parkinson Disease;Movement Disorders	Drug: Altropane (123I) Injection	GE Healthcare	Labcorp Drug Development Inc	Not yet recruiting	18 Years	N/A	All	30	Phase 2	NULL
6	NCT05094011 (ClinicalTrials.gov)	March 1, 2023	20/7/2021	Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects Wit ...	A Phase I Open-Label Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Aut ...	Idiopathic Parkinson's Disease	Biological: Aadipose-Derived Mesenchymal Stem Cells	Taiwan Mitochondrion Applied Technology Co., Ltd.	NULL	Not yet recruiting	45 Years	70 Years	All	9	Phase 1	NULL
7	NCT05766813 (ClinicalTrials.gov)	March 2023	24/2/2023	Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkin ...	A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety o ...	Parkinson Disease	Drug: Lenrispodun;Drug: Placebo	Intra-Cellular Therapies, Inc.	NULL	Recruiting	40 Years	80 Years	All	132	Phase 2	United States
8	NCT05691114 (ClinicalTrials.gov)	February 2023	10/1/2023	Precise Transplantation of Human Amniotic Epithelial Stem Cells Into Lateral Ventricle for Parkinson ...	Precise Transplantation of Human Amniotic Epithelial Stem Cells Into Lateral Ventricle for Parkinson ...	Idiopathic Parkinson's Disease	Biological: hAESCs	Shanghai East Hospital	Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China	Recruiting	40 Years	70 Years	All	18	Phase 1	China
9	NCT05357612 (ClinicalTrials.gov)	January 23, 2023	20/4/2022	Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neuro ...	Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neuro ...	Neurodegenerative Diseases;Parkinson Disease;Parkinson Disease Psychosis	Drug: Pimavanserin	Vanderbilt University Medical Center	ACADIA Pharmaceuticals Inc.	Recruiting	50 Years	85 Years	All	75	Phase 4	United States
10	NCT05699694 (ClinicalTrials.gov)	January 5, 2023	11/1/2023	Clinical Study on the Efficacy of Natural Stem Cell Mobilizers on Parkinson Disease	Open-labeled Pilot Study on the Efficacy of a New Food Supplement Composed of Natural Stem Cell Mobi ...	Parkinson Disease	Dietary Supplement: StemRegen product	Sociedad Española de Medicina Regenerativa y Terapia Celular	NULL	Recruiting	21 Years	90 Years	All	40	N/A	Spain

First Previous1 2 3 4 5…231Next Last